Trial · NCT01257750
Treatment of Corneal Neovascularization With Topical Pazopanib
NCT01257750, Phase 1, Phase 2, Completed, Reza Dana, MD; results first posted 2012-11-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Corneal Neovascularization With Topical Pazopanib. Trials, record NCT01257750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01257750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Corneal Neovascularization With Topical Pazopanib
- NCT number
- NCT01257750
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- Reza Dana, MD
- Conditions
- Corneal Neovascularization
- Interventions
- Pazopanib (5mg/ml)
- First posted
- 2010-12-10
- Last updated
- 2018-01-18
- Results first posted
- 2012-11-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Heart Rate | 12 Weeks | Heart rate through was measured throughout the study to assess subjects for systemic adverse events. |
| Primary | Mean Arterial Pressure | 12 Weeks | Mean arterial pressure was measured throughout the study to assess subjects for systemic adverse events.. |
| Primary | Central Corneal Thickness | 12 Weeks | Pachymetry was used to measure the central corneal thickness of each study subject. Central corneal thickness was measured throughout the study to assess subjects for ocular adverse events. |
| Primary | Intaocular Pressure | 12 Weeks | Intaocular pressure is the measurement of pressure within the eye. Intaocular pressure was measured throughout the study to assess subjects for ocular adverse events. |
| Secondary | Corneal Neovascular Area | Through 12 weeks of Follow-Up | Corneal neovascular area is the measurement of the area of the cornea where new blood vessels are forming. The mean Change in Corneal Neovascular Area from Baseline to 12 Week Time Point is reported below. |
| Secondary | Corneal Invasion Area | 12 Weeks | Corneal Invasion area is the measurement of the fraction of the total corneal area that is invaded by blood vessels. The mean Change in Corneal invasion area from baseline to 12 Week Time Point is reported below. |
| Secondary | Corneal Vessel Length | 12 Weeks | Corneal vessel length is the measurement of the length of the extent of vessels from end to end. The mean change in corneal vessel length from Baseline to 12 Week Time Point is reported below. |
| Secondary | Corneal Vessel Caliber | 12 Weeks | Corneal vessel caliber is the measurement of the diameter of the corneal blood vessels. The mean change in the corneal vessel caliber from baseline to 12 week time point is reported below. |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Heart Rate | 12 Weeks | All enrolled patients were analyzed. | Beats per Minutes | MEAN |
| PRIMARY | Mean Arterial Pressure | 12 Weeks | mmHG | MEAN | |
| PRIMARY | Central Corneal Thickness | 12 Weeks | All enrolled patients were analyzed. | Microns | MEAN |
| PRIMARY | Intaocular Pressure | 12 Weeks | mmHg | MEAN | |
| SECONDARY | Corneal Neovascular Area | Through 12 weeks of Follow-Up | Mean Change in Corneal Neovascular Area (measuring the area of the corneal vessels) from Baseline to 12 Week Time Point. | millimeters squared | MEAN |
| SECONDARY | Corneal Invasion Area | 12 Weeks | millimeters squared | MEAN | |
| SECONDARY | Corneal Vessel Length | 12 Weeks | millimeters | MEAN | |
| SECONDARY | Corneal Vessel Caliber | 12 Weeks | millimeters | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Heart Rate | Pazopanib | 68.7 | Standard Deviation 7.6 | Beats per Minutes | |
| Mean Arterial Pressure | Pazopanib | 90.7 | Standard Deviation 1.4 | mmHG | |
| Central Corneal Thickness | Pazopanib | 590 | Standard Deviation 162 | Microns | |
| Intaocular Pressure | Pazopanib | 16.9 | Standard Deviation 5.3 | mmHg | |
| Corneal Neovascular Area | Pazopanib | 1.5 | Standard Deviation 0.8 | millimeters squared | |
| Corneal Invasion Area | Pazopanib | 3.9 | Standard Deviation 1.8 | millimeters squared | |
| Corneal Vessel Length | Pazopanib | 38.0 | Standard Deviation 17.2 | millimeters | |
| Corneal Vessel Caliber | Pazopanib | 0.0003 | Standard Deviation 0.0005 | millimeters |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pazopanib | 20 | |
| Overall Study | COMPLETED | Pazopanib | 20 | |
| Overall Study | NOT COMPLETED | Pazopanib | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Tearing | Eye disorders | Pazopanib | 10 | 20 | 13 |
| other | Stinging | Eye disorders | Pazopanib | 4 | 20 | 4 |
| other | Dryness | Eye disorders | Pazopanib | 1 | 20 | 1 |
| other | Blurred Vision | Eye disorders | Pazopanib | 1 | 20 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pazopanib | ||
| Total, other adverse events | Pazopanib | 12 | 20 |
| Total, serious adverse events | Pazopanib | 0 | 20 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23233252 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01257750
GET https://conductscience.org/api/trials/v1/NCT01257750/registered